Seeking Alpha

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR) (Marker or the Company), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based ...
Nasdaq

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

HOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for ...
Nasdaq

Marker Therapeutics Says FDA Lifts Partial Clinical Hold On Phase 2 AML Trial Of MT-401

(RTTNews) - Immuno-oncology company Marker Therapeutics, Inc. (MRKR) announced Tuesday that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on its Phase 2 trial ...
Healio

FDA grants orphan drug designation to multi-antigen T-cell therapy for AML

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to MT-401, an allogeneic T-cell therapy for the treatment of acute ...